allergy and allergic rhinitis. Many patients with asthma are poorly controlled by current drug treatment, particularly a subgroup of patients with difficult-to-treat severe asthma, characterized by chronic symptoms, severe exacerbations, progressive loss of lung function, and resistance to corticosteroids. New therapeutic options are therefore highly warranted.
Our patent covers arginase as a new drug target for the treatment of asthma and/or allergic rhinitis, making use of an arginase inhibitor.
1 Arginase is the final enzyme of the hepatic urea cycle, converting l-arginine to l-ornithine and urea. Arginase is also expressed in nonhepatic tissues, including the airways. Two isoforms have been identified, arginases 1 and 2, which are encoded by different genes and are differentially expressed in the body.
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Since l-arginine is also substrate for constitutive and inducible nitric oxide synthases (cNOS and iNOS) yielding l-citrulline and NO, one biological function of extrahepatic arginase may be regulating NO levels through competition with NOS for their common substrate 2 ( Figure 1 ).
Under healthy conditions, NO, derived from cNOS in airway epithelium and inhibitory nonadrenergic-noncholinergic (iNANC) nerves, has a protective role in the airways by inducing bronchodilation as well as inhibiting airway inflammation and mediator release from mast cells. In allergic asthma, arginases can be upregulated by Th2 cytokines (IL-4, IL-13) and TGF-β, causing reduced cNOS-derived NO production and increased production of pro-contractile and pro-inflammatory per-
) by particularly inflammation-induced iNOS, by reduced bioavailability of l-arginine to these enzymes. Moreover, increased arginase activity increases the production of l-ornithine and its downstream products polyamines and l-proline, which may be involved in airway remodeling by inducing cell proliferation, and enhanced collagen production and fibrosis, respectively 2 ( Figure 1 ).
Supporting evidence for this mechanism and thus for a role of arginase in the pathophysiology of allergic asthma and, potentially, other allergic disorders like allergic rhinitis was found in a guinea pig model of allergic asthma. Using this model, we discovered that inhalation of the potent specific arginase inhibitor 2(S)-amino-6-boronohexanoic acid (ABH) considerably reduces the airway sensitivity to inhaled allergen and protects against allergen-induced early and late asthmatic reactions, AHR after these reactions, and airway inflammation. Moreover, ABH acutely reversed AHR after the early and late asthmatic reaction. 
Path leading to the invention and recent developments
In 1996, by performing perfusion experiments in intact airways from allergen-challenged guinea pigs ex vivo, we demonstrated that a deficiency of cNOS-derived NO may contribute to allergen-induced AHR after the early asthmatic reaction. 4 The mechanism of this NO deficiency was unknown. In 1997, we presented some of our data on NO deficiency and asthma on a symposium on the pharmacology of NO in Odense, Denmark. Coincidently, at the same meeting there was the first demonstration that inhibition of arginase by a bona fide arginase inhibitor increased NOS activity in rat alveolar macrophages. 5 Although it took almost 10 years to obtain proof of concept, 2,3 it provided an important clue to the underlying mechanism of the allergen-induced NO deficiency and the therapeutic potential of arginase inhibitors in asthma.
By using a novel potent and specific arginase inhibitor (N ω -hydroxy-nor-l-arginine), we demonstrated that arginase inhibition reduces guinea pig airway responsiveness in vitro by increasing NO production (see Ref.
2 ). In ex vivo studies, using a guinea pig model of allergic asthma, we discovered that arginase activity in the airways is increased after allergen challenge, causing AHR after the early asthmatic reaction by reducing the production of neuronal as well as nonneuronal cNOS-derived NO by reduced bioavailability of l-arginine to the enzyme (Ref. 
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, which has pro-contractile and pro-inflammatory actions in the airways. Collectively, these processes contribute to allergen-induced airway obstruction, airway inflammation and airway hyperresponsiveness, and increased sensitivity to the allergen. Furthermore, the increased synthesis of l-ornithine from arginase provides a precursor for polyamines and l-proline, which stimulate cell proliferation, and collagen production and fibrosis, respectively, causing airway remodeling. IL-4, interleukin-4; IL-13, interleukin-13; NO, nitric oxide; ONOO − , peroxynitrite; TGF-β, transforming growth factor-β [Color figure can be viewed at wileyonlinelibrary.com]
